Patients with a recent suicide attempt and a depressive disorder
Conditions
Interventions
Trade Name: Voltaren
Product Name: Voltaren Enterotablet
Pharmaceutical Form: Tablet
INN or Proposed INN: Diklofenak
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo:
Sponsors
Organisation name was not entered
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Male and female patients aged 18- 65 years. Presence of a recent suicide attempt and symptom of depression Subjects capable of giving consent personally Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Pregnant women and lactating women. Serious medical illness including cardiac, hepatic, renal, respiratory, endocrine, neurologic and hematologic disease that is not stabilized. Inflammatory bowel disease Gastric ulcers or ongoing gastrointestinal bleeding Ongoing treatment with ECT Regular daily treatment with NSAID or glucocortidoids Previous allergic reactions against NSAID, acetylsalisyl acid, sulfonamides, or ingredients in the celecoxib, montelukast or placebo tablets. Psychosis Substance abuses
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objectives of this study are to test the hypotheses that, in suicide attempters with a depressive disorder, diclofenac as an ad on to treatment as usual, decreases suicidality.;Secondary Objective: The secondary objectives of this study are to test the hypotheses that as an ad on to treatment as usual reduce subjective symptoms of e.g. aggressivity, impulsivity, decreased energy, and depressed mood in patients with a recent suicide attempt and a depressive disorder. ;Primary end point(s): | — |
Countries
Sweden
Outcome results
None listed